"Q2 represented a breakout quarter for the IPO market, with record proceeds and a rapid recovery in issuance led by SpaceX’s landmark offering. Beyond the headline deal, a strong pipeline of large IPOs and improving performance signal renewed market momentum, though investor selectivity and sector concentration continue to shape outcomes." Meaghan Miller, Vice President of Global Capital Markets, DFIN
DFIN congratulates the 48 companies that successfully completed a traditional IPO in Q2, as well as the 12 companies that entered the public markets via a SPAC merger and the four companies that completed a direct listing. DFIN is proud to have partnered with a significant number of these issuers, underscoring our strong share of market activity across high-growth and innovative sectors. Our clients this quarter included:
- AEVEX
- Air Global
- Alamar Biosciences
- Applied Aerospace & Defense
- Arxis
- Avalyn Pharma
- Blackstone Digital Infrastructure Trust
- EagleRock Land
- ERock
- Hemab Therapeutics
- Hadron Energy
- INNIO Holding
- ITG
- Kailera Therapeutics
- Kardigan
- Liftoff Mobile
- Madison Air Solutions
- Odyssey Therapeutics
- OPTIMI Health
- Parabilis Medicines
- Rare Earths Americas
- Seaport Therapeutics
- Teamshares
- WhiteHawk Income Corporation
